Bafiertam vs Dimethyl fumarate (Tecfidera)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline
Bafiertam
Marketed by Cycle Pharmaceuticals Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Dimethyl fumarate (Tecfidera)
Marketed by Biogen
NCT00451451 · Phase 3 · completed
This was a large (n=1417), randomized, double-blind, placebo-controlled Phase 3 trial with a hard clinical primary endpoint (annualized relapse rate, independently adjudicated). Both BG00012 dosing arms showed clearly separated confidence intervals from placebo on this primary endpoint (0.224 and 0.198 relapses/year vs 0.401 for placebo), indicating the drug met its primary comparison in the favorable direction, satisfying all the elements of well-designed, positive Phase 3 evidence.
Reported efficacy
Annualized Relapse Rate (2 years): Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo. (met)
Result source: NCT00451451
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bafiertam | Dimethyl fumarate (Tecfidera) |
|---|---|---|
| Annualised relapse rate | —Not reported | 0.2 vs 0.4−0.2 vs placeboNCT004514515 other results
|
| Free of 3-month confirmed disability progression (%) | —Not reported | —Not reported |
| New or enlarging T2 lesions | —Not reported | —Not reported |
Annualised relapse rate
- Bafiertam
- —Not reported
- Dimethyl fumarate (Tecfidera)
- 0.2 vs 0.4−0.2 vs placeboNCT00451451
5 other results
- 0.2 vs 0.4 NCT00451451
- 0.2 vs 0.4 NCT00420212
- 0.2 vs 0.4 NCT00420212
- 0.2 vs 0.5 NCT02283853
- 0.3 vs 0.6 NCT02283853
Free of 3-month confirmed disability progression (%)
- Bafiertam
- —Not reported
- Dimethyl fumarate (Tecfidera)
- —Not reported
New or enlarging T2 lesions
- Bafiertam
- —Not reported
- Dimethyl fumarate (Tecfidera)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bafiertam: 2 of 4 rows · Dimethyl fumarate (Tecfidera): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bafiertam | Dimethyl fumarate (Tecfidera) |
|---|---|---|
| Dropout rate | —a NCT04570670 · Phase 1 | 20.9%240 mg 3 times dailyb NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 13 more results20.9%240 mg twice daily NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 23.1%240 mg TID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 23.2%240 mg BID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 55.8%240 mg twice daily NCT00835770 · Phase 3 · monotherapy 56.8%240 mg three times daily NCT00835770 · Phase 3 · monotherapy 14.8% NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy 21.5%Part 1: BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence —Part 2: BG00012/ BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence — NCT02555215 · Phase 3 · registry result, not featured evidence 27.5% NCT02525874 · Phase 3 · registry result, not featured evidence 9.1% NCT02410200 · Phase 2 · registry result, not featured evidence —Add-on Therapy Period: GA and BG00 NCT01156311 · Phase 2 · registry result, not featured evidence · combination —Add-on Therapy Period: IFNß and BG NCT01156311 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT04570670 · Phase 1 | 7.5%240 mg 3 times dailyb NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 13 more results5.8%240 mg twice daily NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 8.7%240 mg TID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 9.8%240 mg BID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 13%240 mg twice daily NCT00835770 · Phase 3 · monotherapy 14.3%240 mg three times daily NCT00835770 · Phase 3 · monotherapy 10.1% NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy 6.3%Part 1: BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence —Part 2: BG00012/ BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence — NCT02555215 · Phase 3 · registry result, not featured evidence 7.8% NCT02525874 · Phase 3 · registry result, not featured evidence 9.1% NCT02410200 · Phase 2 · registry result, not featured evidence —Add-on Therapy Period: GA and BG00 NCT01156311 · Phase 2 · registry result, not featured evidence · combination —Add-on Therapy Period: IFNß and BG NCT01156311 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 0%a NCT04570670 · Phase 1 | 15.7%240 mg 3 times dailyb NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 13 more results17%240 mg twice daily NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 15.6%240 mg TID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 18%240 mg BID NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 32.1%240 mg twice daily NCT00835770 · Phase 3 · monotherapy 31.3%240 mg three times daily NCT00835770 · Phase 3 · monotherapy 3% NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy 23.1%Part 1: BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence 14%Part 2: BG00012/ BG00012 NCT02283853 · Phase 3 · registry result, not featured evidence 10% NCT02555215 · Phase 3 · registry result, not featured evidence 11.9% NCT02525874 · Phase 3 · registry result, not featured evidence 22.7% NCT02410200 · Phase 2 · registry result, not featured evidence 2.1%Add-on Therapy Period: GA and BG00 NCT01156311 · Phase 2 · registry result, not featured evidence · combination 3.5%Add-on Therapy Period: IFNß and BG NCT01156311 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 240 mg 3 times dailyb flushing 24.1% (placebo 3.6%) multiple sclerosis relapse 23.5% (placebo 40.5%) nasopharyngitis 18.3% (placebo 16%) NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 12 more results240 mg twice daily flushing 30.6% (placebo 3.6%) multiple sclerosis relapse 29% (placebo 40.5%) nasopharyngitis 17.3% (placebo 16%) NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 240 mg TID flushing 31.7% (placebo 4.9%) nasopharyngitis 26.2% (placebo 24.8%) multiple sclerosis relapse 25.7% (placebo 44.4%) NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 240 mg BID flushing 37.3% (placebo 4.9%) multiple sclerosis relapse 26.6% (placebo 44.4%) nasopharyngitis 26.3% (placebo 24.8%) NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 240 mg twice daily multiple sclerosis relapse 37.3% nasopharyngitis 25.3% urinary tract infection 22.6% NCT00835770 · Phase 3 · monotherapy 240 mg three times daily multiple sclerosis relapse 38.6% nasopharyngitis 26% flushing 19% NCT00835770 · Phase 3 · monotherapy abdominal pain 41% flushing 38.5% multiple sclerosis relapse 29.5% NCT02283853 · Phase 3 · registry result, not featured evidence multiple sclerosis relapse 26.3% headache 22.8% covid-19 19.3% NCT02283853 · Phase 3 · registry result, not featured evidence flushing 25% multiple sclerosis relapse 20% abdominal pain 15% NCT02555215 · Phase 3 · registry result, not featured evidence flushing 45.9% multiple sclerosis relapse 18.8% nasopharyngitis 15.1% NCT02525874 · Phase 3 · registry result, not featured evidence flushing 45.5% multiple sclerosis relapse 31.8% abdominal pain 27.3% NCT02410200 · Phase 2 · registry result, not featured evidence flushing 53.2% alanine aminotransferase increased 14.9% diarrhoea 14.9% NCT01156311 · Phase 2 · registry result, not featured evidence · combination flushing 42.1% diarrhoea 31.6% abdominal pain 21.1% NCT01156311 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 10 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dimethyl fumarate (Tecfidera)
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 19 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bafiertam's landscape · Dimethyl fumarate (Tecfidera)'s landscape